Immunodiagnostic Systems Holdings plc announced that Patrik Olof Dahlen, a current non-executive member of the board, has been appointed chief executive officer with immediate effect. Patrik, aged 50, has substantial diagnostic and international industry expertise gained as chief executive officer of Dako and at Perkin Elmer through to his progression to President of Life Sciences. At Dako, Patrik conducted a significant strategic repositioning of the company as a cancer diagnostics provider and a leader in companion diagnostics. As president of Life Sciences at Perkin Elmer, Patrik was instrumental in building the company's diagnostic business with a niche focus on diagnostic systems for neonatal and prenatal screening. Most recently, Patrik acted as CEO for Neurosearch with the specific task of optimizing the commercialization strategy and establishing a global partnership for the company's lead product, Huntexil. Patrik Dahlen is currently a director of QuantiBact A/S and DiaGenic ASA and in the last five years has been a director of Dako A/S, Chempaq A/S, NeuroSearch A/S, Sophion Biosciences A/S, Olink AB, Proxeon A/S and Contura A/S.